Long-term clinical studies confirm that prolonged use of MC4R agonists like setmelanotide is effective in reducing BMI and managing hyperphagia in BBS patients, reinforcing its therapeutic relevance [11]. Here, MC4R is linked to Bardet-Biedl syndrome.